Twist Bioscience (NASDAQ: TWST) lifts FY26 outlook after 19% Q2 growth
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Twist Bioscience reported strong fiscal second quarter 2026 results, highlighted by record revenue of $110.7 million, up 19% from $92.8 million a year earlier and marking the 13th consecutive quarter of sequential growth. DNA Synthesis and Protein Solutions revenue rose 28% to $53.3 million, while NGS Applications revenue increased 12% to $57.4 million, with both segments growing sequentially.
Gross margin improved to 51.6% from 49.6%, reflecting better profitability on each dollar of sales. Operating expenses were mixed: research and development fell to $19.7 million, but selling, general and administrative costs climbed to $76.1 million. The company also recorded $7.2 million in litigation settlement costs tied to a securities class action.
As a result, net loss widened slightly to $44.0 million, or $0.71 per share, compared with $39.3 million, or $0.66 per share, in the prior-year quarter. Adjusted EBITDA improved modestly to a loss of $13.3 million from $14.8 million. Twist ended March 31, 2026 with $172 million in cash, cash equivalents and short‑term investments and shipped products to approximately 2,583 customers.
Management raised full‑year 2026 revenue guidance to a range of $442 million to $447 million, implying 17–19% growth, and continues to target adjusted EBITDA breakeven in the fourth quarter of fiscal 2026 while keeping gross margin above 52% for the year.
Positive
- Record revenue and broad-based growth: Q2 FY26 revenue reached $110.7M, up 19% year over year, with DSPS up 28% to $53.3M and NGS up 12% to $57.4M, marking the 13th straight quarter of sequential growth.
- Margin expansion and upgraded outlook: Gross margin improved to 51.6% from 49.6%, and full‑year revenue guidance was raised to $442–$447M, with management reiterating a target of adjusted EBITDA breakeven in Q4 FY26.
Negative
- Continuing losses despite scale: Net loss increased to $44.0M (or $0.71 per share) from $39.3M (or $0.66) a year earlier, and adjusted EBITDA remained negative at $13.3M.
- Litigation and higher operating costs: The quarter included $7.2M of litigation settlement costs related to a securities class action, while SG&A expenses rose to $76.1M from $63.7M, pressuring profitability.
Insights
Revenue growth is strong and guidance is higher, but losses and legal costs persist.
Twist Bioscience delivered record Q2 FY26 revenue of $110.7M, up 19% year over year, with both DSPS and NGS segments growing and gross margin expanding to 51.6%. This shows solid demand and improving unit economics.
However, operating expenses, particularly SG&A at $76.1M, and a $7.2M litigation settlement charge pushed net loss to $44.0M, slightly worse than last year. Adjusted EBITDA loss narrowed to $13.3M, indicating gradual operating leverage but not yet profitability.
Management raised full‑year revenue guidance to $442–$447M and reiterated a goal of adjusted EBITDA breakeven in Q4 FY26, while targeting gross margin above 52%. The trajectory now hinges on sustaining high‑teens growth, controlling SG&A, and avoiding further one‑off costs over the remaining fiscal 2026 quarters.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Q2 FY26 revenue: $110.7M
DSPS revenue: $53.3M
NGS revenue: $57.4M
+5 more
8 metrics
Q2 FY26 revenue
$110.7M
Three months ended March 31, 2026; up 19% from $92.8M in 2025
DSPS revenue
$53.3M
Q2 FY26; 28% growth vs $41.6M in Q2 FY25
NGS revenue
$57.4M
Q2 FY26; 12% growth vs $51.1M in Q2 FY25
Gross margin
51.6%
Q2 FY26; up from 49.6% in prior-year quarter
Net loss
$44.0M
Q2 FY26; $0.71 per share vs $39.3M, $0.66 in Q2 FY25
Adjusted EBITDA
-$13.3M
Q2 FY26; improved from -$14.8M in Q2 FY25
Cash and investments
$172M
Cash, cash equivalents and short-term investments as of March 31, 2026
FY26 revenue guidance
$442–$447M
Full-year 2026 expected revenue; 17–19% growth
Key Terms
Adjusted EBITDA, Gross margin, Litigation settlement costs, net of recoveries, Non-GAAP financial measures, +1 more
5 terms
Adjusted EBITDA financial
"We continue to anticipate achieving adjusted EBITDA breakeven in the fourth quarter of fiscal 2026"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
Gross margin financial
"Gross margin for the second quarter of fiscal 2026 increased to 51.6% compared to 49.6%"
Gross margin is the difference between how much money a company makes from selling its products and how much it costs to produce them, expressed as a percentage of sales. It shows how efficiently a company is turning sales into profit before other expenses like marketing or salaries. Higher gross margin means the company keeps more money from each sale, which is a good sign of financial health.
Litigation settlement costs, net of recoveries financial
" $7.2 million was booked for litigation settlement costs, net of recoveries in the second quarter of fiscal 2026"
Non-GAAP financial measures financial
"This release includes EBITDA and adjusted EBITDA, which are non-GAAP financial measures"
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
Securities class action regulatory
"We reached a settlement in principle regarding the securities class action for approximately $17.1 million"
A securities class action is a lawsuit brought by a group of investors who claim they lost money because a company or its executives made false or misleading statements about financial performance, risks, or business prospects. Think of it as many people pooling forces to challenge misleading information; it matters to investors because these cases can lead to large settlements or judgments, hurt a company’s reputation, drain cash, and cause share prices to fall or become more volatile.
Earnings Snapshot
Revenue: $110.7M · Guidance included
Q2 FY2026
Revenue
$110.7M
+19% YoY
Gross margin
51.6%
+2.0 pts YoY (from 49.6%)
Net loss
$44.0M
vs $39.3M prior-year quarter
Adjusted EBITDA
-$13.3M
improved from -$14.8M
Guidance
For FY26, Twist expects revenue of $442–$447M with gross margin above 52% and targets adjusted EBITDA breakeven in Q4 FY26.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (I. R. S. Employer Identification No.) | ||||||||||||
(Address of principal executive offices, including ZIP code)
(800 ) 719-0671
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02Results of Operations and Financial Condition.
On May 4, 2026, Twist Bioscience Corporation (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits.
| Exhibit No. | Description | |||||||
| 99.1 | Press release dated May 4, 2026 titled “Twist Bioscience Reports Fiscal Second Quarter 2026 Financial Results” | |||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 4, 2026 | Twist Bioscience Corporation | ||||
| /s/ Judy Yan | |||||
| Judy Yan | |||||
| Assistant General Counsel and Assistant Secretary | |||||
Exhibit 99.1
Twist Bioscience Reports Fiscal Second Quarter 2026 Financial Results
— Record revenue of $110.7 million in 2QFY26; Increase of more than 19% over $92.8 million in 2QFY25; 13th consecutive quarter of sequential growth —
— Gross margin of 51.6% in 2QFY26; Improvement of approximately 2 margin points versus 2QFY25 —
— Revenue guidance raised to $442-$447M; Reiterating Q4 FY26 Adj EBITDA breakeven —
SOUTH SAN FRANCISCO, Calif. -- (May 4, 2026) — Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today reported financial results and business highlights for the second quarter ended March 31, 2026.
"We had a strong performance in the first half of fiscal 2026, ending the second quarter with our thirteenth consecutive quarter of growth. Revenue exceeded guidance, coming in at $110.7 million, growth of over 19% compared to the second quarter of 2025," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "As we look ahead, we remain focused on delivering consistent, measurable growth designed to scale over time. We expect to chart toward profitability while simultaneously building on the strong momentum we are seeing across the portfolio. We continue to anticipate achieving adjusted EBITDA breakeven in the fourth quarter of fiscal 2026 while holding gross margin above 52% for the fiscal year."
See "Non-GAAP Information" below for a discussion of the measure adjusted EBITDA.
FISCAL 2026 SECOND QUARTER FINANCIAL RESULTS
•Revenue: Total revenues for the second quarter of fiscal 2026 grew 19% to $110.7 million compared to $92.8 million for the same period of fiscal 2025.
◦DNA Synthesis and Protein Solutions (DSPS) revenue grew 28% to $53.3 million for the second quarter of fiscal 2026 compared to $41.6 million for the same period of fiscal 2025, and grew 4% sequentially, compared to $51.1 million for the first quarter of fiscal 2026.
◦NGS Applications (NGS) revenue grew 12% to $57.4 million for the second quarter of fiscal 2026 compared to $51.1 million for the same period of fiscal 2025, and grew 9% sequentially, compared to $52.6 million for the first quarter of fiscal 2026.
•Cost of Revenues: Cost of revenues for the second quarter of fiscal 2026 increased to $53.6 million compared to $46.8 million for the same period of fiscal 2025.
•Gross Margin: Gross margin for the second quarter of fiscal 2026 increased to 51.6% compared to 49.6% for the same period of fiscal 2025.
•Research and Development Expenses: Research and development expenses for the second quarter of fiscal 2026 decreased to $19.7 million compared to $23.9 million for the same period of fiscal 2025.
•Selling, General and Administrative Expenses: Selling, general and administrative expenses for the second quarter of fiscal 2026 were $76.1 million compared to $63.7 million for the same period of fiscal 2025.
•Litigation Settlement: We reached a settlement in principle regarding the securities class action for approximately $17.1 million. $7.2 million was booked for litigation settlement costs, net of recoveries in the second quarter of fiscal 2026.
•Net Loss: Net loss for the second quarter of fiscal 2026 increased to $44.0 million, or $0.71 per share, compared to $39.3 million, or $0.66 per share, for the same period of fiscal 2025.
•Adjusted EBITDA: Adjusted EBITDA for the second quarter of fiscal 2026 was $(13.3) million compared to $(14.8) million for the same period of fiscal 2025. See the table included in this release for a reconciliation between adjusted EBITDA, which excludes litigation settlement costs, and net loss attributable to common stockholders, the most directly comparable GAAP financial measure.
•Cash Position: As of March 31, 2026, the company had approximately $172 million in cash, cash equivalents and short-term investments.
Recent Highlights:
•Shipped products to approximately 2,583 customers in the second quarter of fiscal 2026, versus approximately 2,431 in the same period of fiscal 2025.
•Physically shipped approximately 300,000 genes in the second quarter of fiscal 2026, compared with approximately 227,000 in the same period of fiscal 2025.
•Entered into bispecific licensing agreement to become the co-exclusive provider, together with Invenra, of Invenra’s B-Body® bispecific antibody platform, extending Twist’s antibody discovery services.
•Amazon Web Services announced Twist as a wet lab partner for Amazon Bio Discovery, its AI-powered drug discovery application.
•Launched the Twist TrueAmp Library Preparation Kit and Twist PCR-Free WGS Library Preparation Kit, each designed to address a wide range of sample input, including low input and challenging sample types, to enable clinical research.
Fiscal 2026 Financial Guidance
The following statements are based on Twist’s current expectations for fiscal 2026. The following statements are forward-looking, and actual results could differ materially depending on market conditions and the factors set forth under “Forward-Looking Statements” below.
For the full fiscal year 2026, Twist expects:
•Total revenue in the range of $442 million to $447 million, growth of 17% to 19%, compared to prior guidance of $435 to $440 million.
•Gross margin to be above 52% for fiscal 2026
For the third quarter, Twist expects:
•Total revenue of approximately $114 million to $115 million, growth of approximately 19% year over year at the midpoint. As previously discussed, we expect NGS to be the driver of sequential growth in H2 and return to 20% growth by 4Q.
For the fourth quarter, Twist expects:
•To achieve adjusted EBITDA breakeven for the fourth quarter of fiscal 2026
Non-GAAP Information
This release includes EBITDA and adjusted EBITDA, which are non-GAAP financial measures, for the periods presented. EBITDA is defined as net loss adjusted to exclude interest income, income tax expense and depreciation and amortization. Adjusted EBITDA is defined as net loss adjusted to exclude interest income, income tax expense, depreciation and amortization, litigation settlement costs, net of recoveries, other income/expense, net, and stock-based compensation expense. These non-GAAP measures are not in accordance with, or an alternative for, measures prepared in accordance with generally accepted accounting principles (GAAP) and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. We believe that these non-GAAP financial measures, when considered together with our financial information prepared in accordance with GAAP, can enhance investors’ and analysts’ ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. However, non-GAAP information is not superior to financial measures calculated in accordance with GAAP, is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. A reconciliation table of the most comparable GAAP financial measure to the non-GAAP financial measures is included at the end of this press release.
A reconciliation of adjusted EBITDA for the fourth quarter of fiscal 2026 to a corresponding GAAP financial guidance measure is not available on a forward-looking basis because the Company does not provide guidance on GAAP net loss and is not able to present the various reconciling cash and non-cash items between GAAP net loss and adjusted EBITDA without unreasonable effort. In particular, stock-based compensation expense is impacted by the Company’s future hiring and retention needs, as well as the future fair market value of its
common stock, all of which is difficult to predict and is subject to change. The actual amount of these expenses during the fourth quarter of fiscal 2026 will have a significant impact on Twist’s future GAAP financial results.
Conference Call Information
The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its financial results and provide an update on the company’s business. The conference call will be webcast live through the Investor Relations section under the “Company” tab at www.twistbioscience.com. Those parties interested in participating via telephone must register on the Company’s Investor Relations website or by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.
About Twist Bioscience
At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets.
We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal – more experiments, more iterations, more chances for remarkable discoveries.
Together, we stand with customers in the relentless pursuit of progress, backed by enterprise reliability, to shape a healthier and more sustainable future for all. For more information about our products and services, please visit www.twistbioscience.com.
Follow us on LinkedIn | X | YouTube | Instagram | Bluesky
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, projections under the heading “Fiscal 2026 Financial Guidance,” statements regarding future growth and expansion, drivers of future revenue and gross margin growth, estimated annual revenues, ability and
timing to achieve profitability, ability and timing to achieve adjusted EBITDA breakeven and ability to maintain or increase gross margins and Twist’s other expectations regarding its future operations plans and financial performance, introduction of new products, and newly announced partnerships. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; the ability to integrate and leverage artificial intelligence and machine learning technologies to improve operational efficiency, product development, and customer solutions; the ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist’s costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; risks associated with the spin out of Atlas Data Storage; the ability to maintain and enforce intellectual property protection; uncertainty as to economic and market conditions and the impact of adverse economic conditions; and the ability to obtain financing when necessary. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist’s business in general, see Twist’s risk factors set forth in Twist’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 17, 2025. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
For Investors:
Angela Bitting
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com
For Media:
Amanda Houlihan
Communications Manager
774-265-5334
ahoulihan@twistbioscience.com
Twist Bioscience Corporation
Condensed Consolidated Statements of Operations
(Unaudited)
(in thousands)
| Three months ended March 31, | Six months ended March 31, | |||||||||||||||||||||||||
| (In thousands, except per share data) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||||
Revenues | $ | 110,715 | $ | 92,793 | $ | 214,413 | $ | 181,506 | ||||||||||||||||||
| Costs and expenses: | ||||||||||||||||||||||||||
| Cost of revenues | $ | 53,593 | $ | 46,765 | $ | 103,319 | $ | 92,638 | ||||||||||||||||||
| Research and development expenses | 19,695 | 23,917 | 36,825 | 45,224 | ||||||||||||||||||||||
| Selling, general and administrative expenses | 76,085 | 63,671 | 145,827 | 119,849 | ||||||||||||||||||||||
| Litigation settlement costs, net of recoveries | 7,205 | — | 7,205 | — | ||||||||||||||||||||||
| Total costs and expenses | $ | 156,578 | $ | 134,353 | $ | 293,176 | $ | 257,711 | ||||||||||||||||||
| Loss from operations | $ | (45,863) | $ | (41,560) | $ | (78,763) | $ | (76,205) | ||||||||||||||||||
| Interest income | $ | 1,710 | $ | 2,801 | $ | 3,885 | $ | 6,041 | ||||||||||||||||||
| Other income (expense), net | 175 | (394) | 646 | (487) | ||||||||||||||||||||||
| Income tax expense | (43) | (175) | (296) | (271) | ||||||||||||||||||||||
| Net loss | $ | (44,021) | $ | (39,328) | $ | (74,528) | $ | (70,922) | ||||||||||||||||||
| Net loss per share — basic and diluted | $ | (0.71) | $ | (0.66) | $ | (1.21) | $ | (1.19) | ||||||||||||||||||
| Weighted average shares used in computing net loss per share — basic and diluted | 61,702 | 59,649 | 61,387 | 59,403 | ||||||||||||||||||||||
Twist Bioscience Corporation
Condensed Consolidated Balance Sheets
(Unaudited)
(in thousands)
| (In thousands) | March 31, 2026 | September 30, 2025 | ||||||||||||
| Assets | ||||||||||||||
| Current assets: | ||||||||||||||
| Cash and cash equivalents | $ | 122,670 | $ | 183,049 | ||||||||||
| Short-term investments | 49,001 | 49,385 | ||||||||||||
| Accounts receivable, net | 64,153 | 57,019 | ||||||||||||
| Inventories | 33,515 | 28,309 | ||||||||||||
| Prepaid expenses and other current assets | 54,100 | 15,204 | ||||||||||||
| Total current assets | $ | 323,439 | $ | 332,966 | ||||||||||
| Property and equipment, net | 111,226 | 102,283 | ||||||||||||
| Operating lease right-of-use assets | 70,655 | 49,377 | ||||||||||||
| Investment in equity securities | 68,087 | 54,337 | ||||||||||||
| Other non-current assets | 102,807 | 102,898 | ||||||||||||
| Total assets | $ | 676,214 | $ | 641,861 | ||||||||||
| Liabilities and stockholders’ equity | ||||||||||||||
| Current liabilities: | ||||||||||||||
| Accounts payable | $ | 14,682 | $ | 11,094 | ||||||||||
| Accrued compensation | 27,003 | 31,288 | ||||||||||||
| Current portion of operating lease liability | 10,443 | 13,822 | ||||||||||||
| Other current liabilities | 67,848 | 35,202 | ||||||||||||
| Total current liabilities | $ | 119,976 | $ | 91,406 | ||||||||||
| Operating lease liability, net of current portion | 85,398 | 61,750 | ||||||||||||
| Liability related to the sale of future revenue | 15,000 | 15,000 | ||||||||||||
| Other non-current liabilities | 746 | 747 | ||||||||||||
| Total liabilities | $ | 221,120 | $ | 168,903 | ||||||||||
| Total stockholders’ equity | $ | 455,094 | $ | 472,958 | ||||||||||
| Total liabilities and stockholders’ equity | $ | 676,214 | $ | 641,861 | ||||||||||
Twist Bioscience Corporation
Adjusted EBITDA
(Unaudited)
(in thousands)
The following table sets forth a reconciliation between our Adjusted EBITDA and net loss attributable to Twist Bioscience Corporation, the most directly comparable GAAP financial measure, for each of the periods presented:
| Three months ended March 31, | Six months ended March 31, | |||||||||||||||||||||||||
| (In thousands) | 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||||
| GAAP net loss | $ | (44,021) | $ | (39,328) | $ | (74,528) | $ | (70,922) | ||||||||||||||||||
| Add (Deduct) adjustments: | ||||||||||||||||||||||||||
| Interest income | $ | (1,710) | $ | (2,801) | $ | (3,885) | $ | (6,041) | ||||||||||||||||||
| Income tax expense | 43 | 175 | 296 | 271 | ||||||||||||||||||||||
| Depreciation and amortization | 6,414 | 6,402 | 12,608 | 12,784 | ||||||||||||||||||||||
| EBITDA | $ | (39,274) | $ | (35,552) | $ | (65,509) | $ | (63,908) | ||||||||||||||||||
| Add (Deduct) adjustments: | ||||||||||||||||||||||||||
| Litigation settlement costs, net of recoveries | $ | 7,205 | $ | — | $ | 7,205 | $ | — | ||||||||||||||||||
| Other (income) expense, net | (175) | 394 | (646) | 487 | ||||||||||||||||||||||
| Stock-based compensation expense | 18,936 | 20,328 | 32,209 | 32,319 | ||||||||||||||||||||||
| Adjusted EBITDA | $ | (13,308) | $ | (14,830) | $ | (26,741) | $ | (31,102) | ||||||||||||||||||
FAQ
How did Twist Bioscience (TWST) perform in Q2 fiscal 2026?
Twist Bioscience posted record Q2 FY26 revenue of $110.7 million, up 19% year over year. Gross margin improved to 51.6%, but the company still reported a net loss of $44.0 million, or $0.71 per share, slightly wider than last year.
What were Twist Bioscience’s key revenue drivers in Q2 FY26?
Growth was balanced across businesses. DSPS revenue rose 28% to $53.3 million, while NGS revenue increased 12% to $57.4 million. Both segments also grew sequentially versus Q1 FY26, supporting Twist’s thirteenth consecutive quarter of sequential revenue expansion.
Did Twist Bioscience improve profitability metrics in Q2 FY26?
Profitability metrics showed mixed progress. Gross margin expanded to 51.6% from 49.6%, and adjusted EBITDA loss improved to $13.3 million from $14.8 million. However, net loss still widened to $44.0 million, reflecting higher SG&A and litigation settlement costs.
What financial guidance did Twist Bioscience (TWST) provide for fiscal 2026?
Twist raised full‑year 2026 revenue guidance to $442–$447 million, implying 17–19% growth. Management expects gross margin above 52% for the year and continues to anticipate achieving adjusted EBITDA breakeven in the fourth quarter of fiscal 2026.
What is Twist Bioscience’s cash position after Q2 FY26?
As of March 31, 2026, Twist Bioscience held about $172 million in cash, cash equivalents and short‑term investments. This liquidity supports ongoing investment in growth, research and operations while the company works toward its adjusted EBITDA breakeven target.
How did operating expenses and litigation affect Twist Bioscience in Q2 FY26?
Operating expenses were significant. R&D decreased to $19.7 million, but SG&A climbed to $76.1 million. Twist also recorded $7.2 million in litigation settlement costs for a securities class action, contributing to the quarter’s net loss.